Avalo Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held on December 20, 2023. As of the record date (October 12, 2023), the company had 192,382,419 shares outstanding, with approximately 34.88% present or represented by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
- Proposal 1 (Election of Directors): Stockholders elected all five nominees to the Board: June Almenoff, Mitchell Chan, Gilla Kaplan, Garry Neil, and Magnus Persson. All received significant "For" votes ranging from approximately 32.3 million to 34.3 million.
- Proposal 2 (Reverse Stock Split): Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split. The ratio is set between 1-for-5 and 1-for-250, to be determined by the Board. The vote was split, with 34,709,488 votes "For" and 31,638,733 votes "Against."
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2023, with 57,979,549 votes "For."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, or contingencies beyond the corporate actions described.
Key Facts for Investor Verification
- Verify the specific reverse stock split ratio (between 1-for-5 and 1-for-250) once determined by the Board.
- Confirm the effective date of the reverse stock split and its impact on share count and trading price.
- Review the composition of the newly elected Board of Directors.